A significant burden of cancer is due to the presence of predisposition genes in the germline of patients. We offer a range of germline testing for cancer predisposition genes to help clinical geneticists counsel and manage patients with a family history or referred after affected by cancer.
We test not only for the common familial breast, ovarian, bowel and melanoma-associated genes but also for alterations in rarer genes and more unusual familial cancers. Novel assays for SNPs that can be used for a polygenic risk scores are also in development.
Assays are competitively priced and rapid turn around times (<1 week) are available enabling patient decisions on risk reduction surgery are available.